A Phase I Study of Post-Operative Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer.
Latest Information Update: 29 Jul 2013
At a glance
- Drugs Cisplatin (Primary) ; Everolimus (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Planned End Date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.